NRGGU013
OPEN TO ACCRUAL
Phase III SBRT vs Conventional or Moderate Hypofractionation for High-Risk Prostate Cancer
NWU22-12-01
OPEN TO ACCRUAL
PH2 Placebo-Controlled Trial of Urolithin a in Prostate Cancer Undergoing Radical Prostatectomy
S2312
OPEN TO ACCRUAL
Phase III Study of Cabazitaxel w/ or w/o Carboplatin in MCRPC Patients
UW22067
OPEN TO ACCRUAL
PET/CT Characterization of Treatment Resistance of AR-targeted therapies in mCRPC
UW24008
OPEN TO ACCRUAL
Ph 1b, HC-7366 in Combo w/ Belzutifan (WELIREG TM) or Cabozantinib with Inoperable or Metastatic RCC
UW24097
OPEN TO ACCRUAL
Phase II MDRT for oligometastatic prostate cancer treated with ADT in the STAMPEDE trial (METANOVA).
UW24109
OPEN TO ACCRUAL
Ph1: Safety+Tolerability of Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS)
UW24138
OPEN TO ACCRUAL
P3: Xaluritamig vs Cabazitaxel or 2nd Androgen Receptor-Directed Therapy w/progressive mCRPC
UW25025
OPEN TO ACCRUAL
P1: Pilot trial of pTVG-HP+Nivo+targeted ablation of resistant lesions in Non-Castrate RecurrentOMPC
UW25057
OPEN TO ACCRUAL
Ph 1/1b Open-Label, Study of ORIC-944 as a Single Agent or in Combo with AR Pathway Inhibitor in mPC
UW25078
OPEN TO ACCRUAL
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer